Digoxin Is Associated with Increased All-cause Mortality in Patients with Atrial Fibrillation Regardless of Concomitant Heart Failure: A Meta-analysis

Journal of Cardiovascular Pharmacology

Volumn 66, Issue 3, 2015, Pages 270-275

  Wang, Zhi Quan ^a   Zhang, Rui ^a   Chen, Man Tian ^a   Wang, Qun Shan ^a   Zhang, Yi ^a   Huang, Xiao Hong ^a   Wang, Jun ^a   Yan, Jian Hua ^a   Li, Yi Gang ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

all cause mortality; atrial fibrillation; digoxin; heart failure; meta analysis

Indexed keywords

DIGOXIN; ANTIARRHYTHMIC AGENT;

ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; DRUG FATALITY; DRUG PREFERENCE; HEART FAILURE; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; COMPLICATION; FACTUAL DATABASE; META ANALYSIS; MORTALITY; STATISTICAL ANALYSIS; TRENDS;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DIGOXIN; HEART FAILURE; HUMANS; MORTALITY;

EID: 84942016697     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000274     Document Type: Article

References (29)

1. Hauptman PJ, Kelly RA. Digitalis. Circulation. 1999;99:1265-1270.
2. Kelly RA, Smith TW. Digoxin in heart failure: implications of recent trials. J Am Coll Cardiol. 1993;22:107A-112A.
3. Yusuf S, Wittes J, Bailey K, et al. Digitalis - a new controversy regarding an old drug. The pitfalls of inappropriate methods. Circulation. 1986;73:14-18.
4. Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109:2959-2964.
5. Chao TF, Liu CJ, Chen SJ, et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study. Can J Cardiol. 2014;30:1190-1195.
6. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF Study. J Am Coll Cardiol. 2014;64:660-668.
7. Freeman JV, Reynolds K, Fang M, et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015;8:49-58.
8. Pastori D, Farcomeni A, Bucci T, et al. Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. Int J Cardiol. 2014;180C:1-5.
9. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients (greater-than or equal to) 65 years of age with versus without heart failure. Am J Cardiol. 2014;114:401-406.
10. Friberg L, Hammar N, Rosenqvist M. Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). Heart. 2010;96:275-280.
11. Rodriguez-Manero M, Otero-Ravina F, Garcia-Seara J, et al. Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin: results from the AFBAR study. Rev Esp Cardiol (Engl Ed). 2014;67:890-897.
12. Patel NJ, Hoosien M, Deshmukh A, et al. Digoxin significantly improves all-cause mortality in atrial fibrillation patients with severely reduced left ventricular systolic function. Int J Cardiol. 2013;169:e84-e86.
13. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin - analysis from the AFFIRM study. Eur Heart J. 2013;34:1481-1488.
14. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34:1489-1497.
15. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
17. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
18. Hallberg P, Lindback J, Lindahl B, et al. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol. 2007;63:959-971.
19. Fauchier L, Grimard C, Pierre B, et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol. 2009;103:248-254.
20. Hvidtfeldt MW, Andersson C, Mikkelsen A, et al. Safety in rate control medication in patients with atrial fibrillation: a nationwide study. Eur Heart J. 2013;34:750.
21. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
22. Keene ON. Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trials. Stat Med. 2002;21:3687-3700.
23. McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9:403-425.
24. Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart. 2008;94:191-196.
25. Lip GY, Metcalfe MJ, Dunn FG. Diagnosis and treatment of digoxin toxicity. Postgrad Med J. 1993;69:337-339.
26. Yang EH, Shah S, Criley JM. Digitalis toxicity: a fading but crucial complication to recognize. Am J Med. 2012;125:337-343.
27. Chirinos JA, Castrellon A, Zambrano JP, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm. 2005;2:525-529.
28. Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulator in heart failure? Circulation. 1991;84:2181-2186.
29. Vardas PE, Kanoupakis EM, Kochiadakis GE, et al. Effects of long-term digoxin therapy on heart rate variability, baroreceptor sensitivity, and exercise capacity in patients with heart failure. Cardiovasc Drugs Ther. 1998;12:47-55.